News from orexo A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Mar 28, 2023, 09:45 ET Orexo publishes the Annual and Sustainability Report for 2022

Orexo's Annual and Sustainability Report for 2022 has been published and can be downloaded at, www.orexo.com, where it is also available in Swedish...

Mar 28, 2023, 09:23 ET Orexo publishes the Annual and Sustainability Report for 2022

Orexo's Annual and Sustainability Report for 2022 has been published and can be downloaded at, www.orexo.com, where it is also available in Swedish...

Mar 15, 2023, 14:07 ET Orexo postpones publication of the Annual Report

Orexo AB (publ), (STO:ORX) (OTCQX:ORXOY), has resolved to postpone the publication of the Annual Report for 2022 to March 28, 2023. The previously...

Mar 15, 2023, 14:04 ET Orexo postpones publication of the Annual Report

Orexo AB (publ), (STO:ORX) (OTCQX:ORXOY), has resolved to postpone the publication of the Annual Report for 2022 to March 28, 2023. The previously...

Mar 15, 2023, 09:55 ET Notice of Annual General Meeting of Orexo

The shareholders in Orexo AB (publ), reg. no. 556500-0600, registered office Uppsala, are summoned to the annual general meeting, to be held on...

Mar 15, 2023, 09:52 ET Notice of Annual General Meeting of Orexo

The shareholders in Orexo AB (publ), reg. no. 556500-0600, registered office Uppsala, are summoned to the annual general meeting, to be held on...

Feb 03, 2023, 02:56 ET Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose

Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces the submission of a New Drug Application (NDA) to the US Food and Drug Administration...

Feb 03, 2023, 02:45 ET Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose

Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces the submission of a New Drug Application (NDA) to the US Food and Drug Administration...

Jan 26, 2023, 02:25 ET Orexo Interim Report Q4 2022, incl. Full Year Report

Important steps forward in a challenging environment Q4 2022 highlights Total net revenues of SEK 156.1 m (144.0) EBITDA of SEK -53.1 m (-48.5),...

Jan 26, 2023, 02:23 ET Orexo Interim Report Q4 2022, incl. Full Year Report

Important steps forward in a challenging environment Q4 2022 highlights Total net revenues of SEK 156.1 m (144.0) EBITDA of SEK -53.1 m (-48.5),...

Jan 09, 2023, 02:15 ET Orexo initiates exploratory feasibility studies of amorphOX® with two leading biopharmaceutical and vaccine companies

Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces the company has initiated two exploratory feasibility studies, applying the proprietary...

Jan 09, 2023, 02:10 ET Orexo initiates exploratory feasibility studies of amorphOX® with two leading biopharmaceutical and vaccine companies

Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces the company has initiated two exploratory feasibility studies, applying the proprietary...

Nov 03, 2022, 03:40 ET Orexo Interim Report Q3 2022

Advancing the pipeline facilitating future growth Q3 2022 highlights Total net revenues of SEK 161.0 m (145.9) EBITDA of SEK -32.4 m (-47.4), EBITDA...

Nov 03, 2022, 03:39 ET Orexo Interim Report Q3 2022

Advancing the pipeline facilitating future growth Q3 2022 highlights Total net revenues of SEK 161.0 m (145.9) EBITDA of SEK -32.4 m (-47.4), EBITDA...

Oct 28, 2022, 07:00 ET Orexo announces last patient enrolled in pivotal study evaluating the efficacy of MODIA® in combination with sublingual buprenorphine/ naloxone for the treatment of OUD

Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces the last participant has enrolled in the pivotal study of the digital therapeutic MODIA®...

Oct 28, 2022, 02:24 ET Orexo announces last patient enrolled in pivotal study evaluating the efficacy of MODIA® in combination with sublingual buprenorphine/ naloxone for the treatment of OUD

Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces the last participant has enrolled in the pivotal study of the digital therapeutic MODIA® ...

Oct 28, 2022, 02:21 ET Orexo announces last patient enrolled in pivotal study evaluating the efficacy of MODIA® in combination with sublingual buprenorphine/ naloxone for the treatment of OUD

Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces the last participant has enrolled in the pivotal study of the digital therapeutic MODIA® ...

Oct 26, 2022, 02:53 ET Orexo appoints Edward Kim, M.D., as new Chief Medical Officer

Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today welcomes Edward (Ed) Kim, M.D., as new Chief Medical Officer (CMO). Ed Kim will succeed Michael...

Oct 26, 2022, 02:49 ET Orexo appoints Edward Kim, M.D., as new Chief Medical Officer

Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today welcomes Edward (Ed) Kim, M.D., as new Chief Medical Officer (CMO). Ed Kim will succeed Michael...

Oct 17, 2022, 09:34 ET Orexo´s Nomination Committee for the Annual General Meeting 2023

Prior to the Annual General Meeting (AGM) that will take place on April 18, 2023, a Nomination Committee has been appointed comprising the same...

Oct 17, 2022, 09:33 ET Orexo´s Nomination Committee for the Annual General Meeting 2023

Prior to the Annual General Meeting (AGM) that will take place on April 18, 2023, a Nomination Committee has been appointed comprising the same...

Oct 11, 2022, 02:37 ET Orexo announces positive data from phase 1 clinical study for OX640 - a nasal epinephrine rescue medication for allergic reactions

Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces positive results from the first explorative human clinical study (OX640-001) for its...

Oct 11, 2022, 02:29 ET Orexo announces positive data from phase 1 clinical study for OX640 - a nasal epinephrine rescue medication for allergic reactions

Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces positive results from the first explorative human clinical study (OX640-001) for its...

Sep 07, 2022, 10:50 ET Orexo's partner Trinity Health today announces the availability of vorvida® and deprexis® to patients

Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces the Integrated Healthcare System, Trinity Health in North Dakota, in partnership with...

Sep 01, 2022, 02:49 ET First patent issued in Europe for Orexo's adrenaline product OX640

Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces that the European Patent Office (EPO) has granted the first European patent specifically...